The EPS projection of Dolby Laboratories (NYSE:DLB) for quarter ended 2016-09-30 is $0.29. Last week, the projection for EPS was $0.29 against target of $0.29, a month earlier. While 2-months ago, this projection was $0.29 versus forecast of $0.29a quarter months earlier, posting a deviation of 0%.
Dolby Laboratories (NYSE:DLB) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 4.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 0, and 0, correspondingly.
The per-share earnings downgrade for Dolby Laboratories (NYSE:DLB) in the preceding 30 and 120 were 0 and 4. While in 60 and 90 days were 0, and 4, in that order.
Dolby Laboratories (NYSE:DLB) EPS target was $0.29 for the quarter closed 2. It was based on 5 calls. As on 2016-04-27 the EPS was $0.66. The change was $0.2, posting a deviation of 43.48%. The price projections gave a standard deviation of 0.01.
Quarterly Sales Estimates
Dolby Laboratories (NYSE:DLB) sales prediction for the fiscal 2017 stands at $259.043 and the median estimate is at $257.727. Almost 4 analysts gave sales target.
Among this, the highest sales estimate is $263.93 while the lowest target is $256.79 showing standard deviation of 3.335%.
As many as 4 analysts have positive sales targets revision while 4 reduced sales estimates, posting a deviation of 0%.
Last month, 4 experts have positive sales number revision. Also, 4 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast, posting a deviation of -4.971%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...